重庆兴泰濠制药有限公司 (Sintaho)

Overview

Chongqing Sintaho Pharmaceutical Co., Ltd. (兴泰濠制药, Sintaho) was founded in 2016 as an active pharmaceutical ingredient (API) company. Its stated scope covers research and development, production, regulatory registration, and market development for international customers.

Focus areas

• Highly potent and cytotoxic APIs
• Peptides
• XDC compounds

Manufacturing and services

• A cytotoxic API production line
• An OEB5 high-potency API production line
• A peptide production line

The company states these lines can provide mature CDMO and CMO services to global partners. It also supplies APIs for its own products.

Regulatory and quality

• States that its products have received regulatory approvals in more than 30 countries, including China, the United States, Canada, and the EU.
• States that it passed FDA on-site inspections in 2024 and 2025.
• Reports experience with audits and inspections by NMPA, FDA, EDQM, and PMDA.

Recognition

The company lists national high-tech enterprise status, national specialized and sophisticated "little giant" enterprise status, a Chongqing enterprise technology center designation, and a Chongqing hazardous waste treatment benchmark enterprise designation.

Mission

The stated mission is "producing high-quality medicines for human health," with the aim of becoming a reliable supplier in the global pharmaceutical supply chain.